PMID- 31586635
OWN - NLM
STAT- MEDLINE
DCOM- 20200325
LR  - 20200325
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 864
DP  - 2019 Dec 1
TI  - Isorhamnetin alleviates esophageal mucosal injury in a chronic model of reflux 
      esophagitis.
PG  - 172720
LID - S0014-2999(19)30672-7 [pii]
LID - 10.1016/j.ejphar.2019.172720 [doi]
AB  - Gastro-esophageal reflux disease is one of the most common disorders in 
      gastroenterology. The aim of this work was to investigate the protection of 
      isorhamnetin against esophageal mucosal injury in rats with chronic reflux 
      esophagitis (RE). Chronic RE model was established through fundus ligation and 
      partial obstruction of the pylorus in rats. Then, the rats were treated with 
      isorhamnetin (5 mg/kg) daily for a period of 14 days. Through histological and 
      gross assessment, it was found that administration of isorhamnetin alleviated 
      esophageal mucosal injury in RE rats. Treatment of RE rats with isorhamnetin 
      improved esophageal barrier function, through upregulating proteins expression of 
      occludin and zonula occludens-1 (ZO-1) and downregulating proteins expression of 
      matrix matalloproteinases-3 (MMP3) and -9. Administration of isorhamnetin 
      decreased CD68-positive cells and mRNA levels of IL-6, TNF-alpha, and IL-1beta in the 
      esophagus of RE rats. Administration of isorhamnetin downregulated inducible 
      nitric oxide synthase (iNOS) protein expression and decreased production of 
      nitric oxide (NO) and 3-nitrotyrosin in the esophagus of RE rats. Administration 
      of isorhamnetin enhanced heme oxygenase-1 (HO-1) activities and reduced 
      malondialdehyde (MDA) levels in esophagus of RE rats. Additionally, treatment 
      with isorhamnetin inhibited p38 MAPK and NFkappaB activation in RE esophagus. In 
      conclusion, isorhamnetin attenuated esophageal mucosal injury in rats with 
      chronic RE, possibly by suppressing formation of cytokines and infiltration of 
      inflammatory cells, inhibiting p38 and NFkappaB pathways, and enhancing HO-1 
      activity.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Liu, Gang
AU  - Liu G
AD  - Department of Digestive Diseases, 900 Hospital of the Joint Logistics Team, 
      Fuzhou, China.
FAU - Jiang, Chuanshen
AU  - Jiang C
AD  - Department of Digestive Diseases, 900 Hospital of the Joint Logistics Team, 
      Fuzhou, China.
FAU - Li, Dazhou
AU  - Li D
AD  - Department of Digestive Diseases, 900 Hospital of the Joint Logistics Team, 
      Fuzhou, China.
FAU - Yao, Lijia
AU  - Yao L
AD  - Department of Digestive Diseases, 900 Hospital of the Joint Logistics Team, 
      Fuzhou, China.
FAU - Lin, Yanfang
AU  - Lin Y
AD  - Department of Digestive Diseases, 900 Hospital of the Joint Logistics Team, 
      Fuzhou, China.
FAU - Wang, Baoshan
AU  - Wang B
AD  - Department of Digestive Diseases, 900 Hospital of the Joint Logistics Team, 
      Fuzhou, China.
FAU - Qiu, Jianting
AU  - Qiu J
AD  - Department of Digestive Diseases, 900 Hospital of the Joint Logistics Team, 
      Fuzhou, China.
FAU - Wang, Weisi
AU  - Wang W
AD  - Department of Digestive Diseases, 900 Hospital of the Joint Logistics Team, 
      Fuzhou, China.
FAU - Wang, Wen
AU  - Wang W
AD  - Department of Digestive Diseases, 900 Hospital of the Joint Logistics Team, 
      Fuzhou, China. Electronic address: wangwenfj@163.com.
LA  - eng
PT  - Journal Article
DEP - 20191003
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (NF-kappa B)
RN  - 07X3IB4R4Z (3-methylquercetin)
RN  - 9IKM0I5T1E (Quercetin)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Animals
MH  - Chronic Disease
MH  - Disease Models, Animal
MH  - Esophageal Mucosa/*drug effects/*pathology
MH  - Esophagitis, Peptic/*drug therapy/metabolism/*pathology
MH  - Male
MH  - NF-kappa B/metabolism
MH  - Oxidative Stress/drug effects
MH  - Quercetin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - p38 Mitogen-Activated Protein Kinases/metabolism
OTO - NOTNLM
OT  - Inflammation
OT  - Isorhamnetin
OT  - Nitric oxide
OT  - Oxidative stress
OT  - Reflux esophagitis
EDAT- 2019/10/07 06:00
MHDA- 2020/03/26 06:00
CRDT- 2019/10/07 06:00
PHST- 2019/05/24 00:00 [received]
PHST- 2019/10/02 00:00 [revised]
PHST- 2019/10/02 00:00 [accepted]
PHST- 2019/10/07 06:00 [pubmed]
PHST- 2020/03/26 06:00 [medline]
PHST- 2019/10/07 06:00 [entrez]
AID - S0014-2999(19)30672-7 [pii]
AID - 10.1016/j.ejphar.2019.172720 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2019 Dec 1;864:172720. doi: 10.1016/j.ejphar.2019.172720. Epub 
      2019 Oct 3.